Welcome to our dedicated page for Dexterra Group news (Ticker: $HZNOF), a resource for investors and traders seeking the latest updates and insights on Dexterra Group stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Dexterra Group's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Dexterra Group's position in the market.
Dexterra announces the renewal of its normal course issuer bid (NCIB) approved by the Toronto Stock Exchange, effective from May 23, 2024, to May 22, 2025. The NCIB allows Dexterra to repurchase up to 165,600 common shares, less than 1% of the total 64,147,229 shares outstanding as of May 16, 2024. Dexterra believes its shares are undervalued and considers the repurchase an attractive investment. Under the previous NCIB, Dexterra repurchased 1,134,400 shares at an average price of C$5.78 each, totaling C$6,556,832. The company also entered an automatic share purchase plan (ASPP) with a broker to facilitate repurchases during trading black-outs.
Dexterra Group Inc. reported a consolidated revenue of $231.6 million for Q1 2024, a 7.2% increase from Q1 2023, driven by new contracts in IFM and strong activity in WAFES. Adjusted EBITDA was $19.6 million, slightly down from $19.8 million in Q1 2023. Net earnings from continuing operations stood at $4.4 million, while the net loss, impacted by discontinued Modular operations, was $3.6 million. Free Cash Flow improved to $10.6 million from a deficit of $5.1 million in Q1 2023. The acquisition of CMI enhanced Dexterra's U.S. IFM presence. However, debt increased to $132.7 million, primarily due to the CMI acquisition and capital expenditures.
